Hausegger K A, Fueger G F, Ebner F, Urban C
Karl-Franzens-Universität Graz.
Nuklearmedizin. 1989 Feb;28(1):34-40.
The significance and indications of MIBG scintigraphy are critically assessed. The results are compared with the results of whole-body bone scintigraphy, computed tomography (CT) and magnetic resonance tomography (MRT), and are related to values of catecholamine metabolites in 24-h urines. In our patients (10 histologically proven cases) MIBG scintigraphy turned out to be most useful in tumor follow-up. In contrast, the significance was much lower in primary tumor diagnosis and tumor staging as the exact primary diagnosis was established by other means such as CT, MRT, MDP whole-body scan, urine chemistry and bone marrow biopsy in all cases. MIBG scintigraphy in diagnostic imaging of neuroblastoma is an additive diagnostic tool and is called for in (1) tumour follow-up (progress, recurrencies, metastases); (2) primary diagnosis if the primary tumour has not been localized by means of CT or MRT; and (3) tumour staging to differentiate stage IV disease from lower stages as long as stage IV disease has not been established by bone-marrow biopsy or MDP whole-body scan.
对间碘苄胍(MIBG)闪烁扫描术的意义和指征进行了严格评估。将结果与全身骨闪烁扫描、计算机断层扫描(CT)和磁共振断层扫描(MRT)的结果进行比较,并与24小时尿液中儿茶酚胺代谢产物的值相关联。在我们的患者(10例经组织学证实的病例)中,MIBG闪烁扫描术在肿瘤随访中最为有用。相比之下,在原发性肿瘤诊断和肿瘤分期中的意义要低得多,因为在所有病例中,确切的原发性诊断是通过其他手段如CT、MRT、亚甲基二膦酸盐(MDP)全身扫描、尿液化学分析和骨髓活检来确立的。MIBG闪烁扫描术在神经母细胞瘤的诊断成像中是一种辅助诊断工具,适用于以下情况:(1)肿瘤随访(进展、复发、转移);(2)如果原发性肿瘤未通过CT或MRT定位,则用于原发性诊断;(3)肿瘤分期,以区分IV期疾病与较低分期,前提是尚未通过骨髓活检或MDP全身扫描确立IV期疾病。